Phosphocreatine is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of creatine monohydrate varies by country and intended use. In some jurisdictions it is sold as a dietary supplement, while in others it may be treated as a food ingredient or a pharmaceutical raw material. Pharmacopeial monographs, where available, define identification, assay limits, and impurity thresholds. Manufacturers often follow these monographs or internal specifications to ensure batch-to-batch consistency. Analytical method validation is important because different methods can yield different apparent purity values if sample preparation or detection conditions are not controlled.
Quality control for creatine monohydrate begins with identity confirmation and assay determination. Laboratories commonly use high-performance liquid chromatography with ultraviolet detection, often after derivatization or using a suitable column, to quantify creatine. Karl Fischer titration measures water content, which helps verify the monohydrate stoichiometry. Additional tests screen for heavy metals, residual solvents, and microbial contamination depending on the intended use. These tests establish composition and purity rather than biological effect.
Stability studies examine how creatine monohydrate changes under controlled temperature and humidity. The solid is generally stable when kept dry, but moisture can promote hydrolysis to creatinine, especially in solution or at elevated temperatures. Color, odor, and assay values are monitored over time to detect degradation. Because degradation pathways depend on storage conditions, shelf-life claims should specify the tested packaging, temperature, and humidity. Open questions remain about the long-term behavior of different crystal habits and particle sizes.
The compound was identified in the nineteenth century after chemists isolated a nitrogenous substance from meat extracts. Later work established its role in muscle energy metabolism and its conversion to phosphocreatine. Chemical synthesis of creatine followed, and industrial production made the monohydrate widely available as a purified powder. Interest expanded in the late twentieth century when researchers began studying creatine supplementation and muscle physiology. Historical accounts sometimes differ on exact dates and attributions, but the broad sequence from tissue extracts to synthetic production is well documented.
In the body, creatine is obtained from dietary meat and fish and is also synthesized from arginine, glycine, and methionine. Muscle stores creatine and phosphocreatine, which participate in the rapid regeneration of adenosine triphosphate during short, intense activity. The monohydrate form is used in research because it is chemically defined, stable as a dry solid, and relatively inexpensive to produce. Questions remain about whether other creatine forms offer meaningful advantages in absorption or tissue retention, and findings vary across studies and populations.
Creatine monohydrate is a crystalline compound formed from creatine and one molecule of water. Creatine itself is a nitrogen-containing organic acid that occurs in vertebrate muscle and other tissues. The monohydrate designation refers to the water included in the crystal lattice, not to water added during manufacturing. Its chemical formula is commonly written as C4H9N3O2·H2O. The solid is typically a white, odorless powder with low solubility in water at room temperature. It is one of several creatine forms described in scientific and commercial literature.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Creatine hydrate; N-carbamimidoyl-N-methylglycine monohydrate | Synonyms vary by naming convention |
| Typical assay method | HPLC-UV | Often paired with a reference standard |
| Water content method | Karl Fischer titration | Confirms monohydrate stoichiometry |
| Degradation product | Creatinine | Forms more readily in solution and with heat |
| Typical storage temperature | 15–25 °C | Keep dry and away from direct sunlight |
Several creatine forms are sold, including monohydrate, anhydrous, hydrochloride, nitrate, citrate, and blends. Once dissolved, these forms deliver creatine, but they differ in molar mass, solubility, counterions, and water content. Creatine monohydrate has the largest body of published human data among these forms. Questions remain about whether any alternative form offers meaningful advantages in absorption, tolerability, or tissue uptake under practical conditions. The hydrate form's lower creatine content by mass is a compositional fact, not a statement about effectiveness.
Creatine monohydrate is a crystalline compound formed when one molecule of creatine associates with one molecule of water in the solid lattice. Its molecular formula is C4H11N3O3, and its molar mass is about 149.15 grams per mole. The material appears as a white, odorless powder that dissolves sparingly in water at room temperature. The monohydrate designation distinguishes it from anhydrous creatine, which lacks the bound water and has a lower molar mass. This hydrate is the most common commercial form of creatine used in nutritional and research settings.
Quality assessment of creatine monohydrate typically uses high-performance liquid chromatography to separate creatine from creatinine and other impurities. Other methods include nuclear magnetic resonance spectroscopy, titration, and infrared spectroscopy for identity confirmation. Purity is often reported as a percentage of the labeled compound on a dry basis, while moisture content is measured separately. Because different analytical methods have different selectivity, comparing purity values across sources requires attention to the method and sample preparation.
In dry solid form, creatine monohydrate is relatively stable when protected from moisture and heat. The crystal lattice includes water, and exposure to high humidity can cause caking or gradual changes in powder flow. Elevated temperatures may accelerate decomposition, particularly if moisture is present. Studies generally report that sealed, dry material retains acceptable purity for extended periods, although exact shelf life depends on packaging and storage conditions. Light exposure is not usually considered a major factor for this compound.
In aqueous solution, creatine monohydrate exists mainly as a zwitterion, carrying both a positive guanidinium charge and a negative carboxylate charge. This charge separation raises water solubility relative to many neutral organic solids and helps explain its behavior in analytical separations. The monohydrate can lose its water of crystallization under sustained heat or low humidity, converting toward anhydrous creatine. Such transitions matter for mass balance calculations because the hydrate contributes water mass that is not part of the active creatine molecule.
The term creatine monohydrate is often shortened to creatine in casual usage, though other creatine forms exist, including citrate, nitrate, and hydrochloride salts. These alternative forms differ in solubility, pH behavior, and the amount of creatine delivered per unit mass. Regulatory categories vary by country: some jurisdictions treat it as a food ingredient, while others place it under supplement or drug frameworks depending on claims and presentation. Standard reference texts list it as a naturally occurring nitrogenous organic acid rather than a vitamin or mineral.
Creatine monohydrate is a crystalline organic compound formed from creatine and water in a one-to-one ratio. It belongs to the guanidino family and contains a methylated guanidine group attached to an acetate-like chain. The solid is commonly described as a white, odorless powder with a mildly bitter taste. Its molecular formula is C4H11N3O3·H2O, and the hydrated form is the most widely traded grade. The compound occurs naturally in vertebrate muscle and brain tissue, where it participates in rapid energy buffering.
Solid creatine monohydrate is generally stable when kept cool and dry, but it can hydrolyze to creatinine over time. Moisture, heat, and acidic conditions accelerate this conversion, which reduces assay values and changes the material's properties. Creatinine is a cyclic dehydration product that is also a normal human metabolite, so its presence in a sample is not necessarily a health concern by itself. In quality testing, creatinine is monitored as a marker of degradation and purity.
Identity and purity are assessed with several complementary methods. High-performance liquid chromatography can separate creatine from creatinine and related impurities, often with ultraviolet detection. Nuclear magnetic resonance and infrared spectroscopy provide structural confirmation, while Karl Fischer titration measures water content. Elemental analysis and mass spectrometry may be used for additional confirmation, especially in research or forensic settings. No single method captures every quality attribute, so laboratories typically combine results and compare them against a specification.
3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech, a company founded by Berislav Zlokovic. It is a genetically engineered variant of activated protein C designed to reduce anticoagulant activity while preserving its cytoprotective and anti-inflammatory properties. This recombinant protein is created by substituting three lysine residues with alanines, thereby minimizing the risk of bleeding associated with native activated protein C. 3K3A-APC exerts its therapeutic effects by targeting protease-activated receptor 1 (PAR1) pathway. A Phase 3 clinical trial was scheduled to start when the NIH paused the trial on November 16, 2023, due to concerns about falsification of data in the studies supporting the clinical trial. The drug was also being assessed for the treatment of Alzheimer's disease, and is currently being evaluated by Dermatherix for wound care.
ASBMB hosts and sponsors numerous meetings each year. The annual meeting is held each April in conjunction with the Experimental Biology meeting. Additionally, themed special symposia are organized throughout the year. The society also produces webinars throughout the year focused on topics related to scientific research, professional development and education. The society offers twenty-five different awards, grants, and scholarships.
Cryptic binding sites are the binding sites that are transiently formed in an apo form or that are induced by ligand binding. Considering the cryptic binding sites increases the size of the potentially "druggable" human proteome from ~40% to ~78% of disease-associated proteins. The binding sites have been investigated by: support vector machine applied to "CryptoSite" data set, Extension of "CryptoSite" data set, long timescale molecular dynamics simulation with Markov state model and with biophysical experiments, and cryptic-site index that is based on relative accessible surface area.
The Bergmann degradation makes use of the azide degradation described by the Curtius rearrangement. Curtius also attempted to degrade benzoylated amino acids; however, his method involved splitting the carbamate with strongly energetic treatment with acids, which lead to decomposition of the resultant aldehyde and acid amides. This convinced Bergmann that Curtius' azide degradation could be followed by treatment with benzyl alcohol (his carbobenzoxy method) to isolate the resultant amino acid aldehyde and residual peptide amide for sequencing purposes.
Sources: en.wikipedia.org
Aβ is formed after sequential cleavage of the amyloid precursor protein (APP), a transmembrane glycoprotein of undetermined function. APP can be cleaved by the proteolytic enzymes α-, β- and γ-secretase; Aβ protein is generated by successive action of the β and γ secretases. The γ secretase, which produces the C-terminal end of the Aβ peptide, cleaves within the transmembrane region of APP and can generate a number of isoforms of 30–51 amino acid residues in length. The most common isoforms are Aβ40 and Aβ42; the longer form is typically produced by cleavage that occurs in the endoplasmic reticulum, while the shorter form is produced by cleavage in the trans-Golgi network.
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis, under development by Anthos Therapeutics. It is anti-factor XI antibody. The hope behind its development is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding. It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke. Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban. Antibody Monoclonal antibody Immunology
A particular challenge in analysing AlphaFold models is distinguishing genuine topology from structural prediction artefacts. A high confidence score does not by itself guarantee that a predicted chain crossing is correct, and incorrect modelling of termini or flexible regions may change the calculated topology. AlphaKnot 2.0 therefore provides several measures intended to help evaluate a predicted knot, including the pLDDT values of the complete chain and knot core, the confidence near the boundaries of the knot core, and detection of unusually close contacts between Cα atoms. Users can also compare AlphaFold predictions with independently generated ESMFold models for shorter proteins. Because automated analysis at the scale of the AlphaFold database cannot be manually verified structure by structure, AlphaKnot 2.0 introduced a user annotation system. Database entries can be assessed by users as a knot, artifact, or unsure, allowing potentially incorrect predictions to be flagged for further consideration.
GOT1/cAST, the cytosolic isoenzyme derives mainly from red blood cells and heart. GOT2/mAST, the mitochondrial isoenzyme is present predominantly in liver. These isoenzymes are thought to have evolved from a common ancestral AST via gene duplication, and they share a sequence homology of approximately 45%. AST has also been found in a number of microorganisms, including E. coli, H. mediterranei, and T. thermophilus. In E. coli, the enzyme is encoded by the aspCgene and has also been shown to exhibit the activity of an aromatic-amino-acid transaminase (EC 2.6.1.57).
From 2011, new cars should have brake assist system in the EU, according to The Pedestrian Protection Regulation (EC) 78/2009. Starting in 2012, all cars under 10,000 lbs. sold in the US are required to have Electronic Stability Control. In 2014, ESP (Electronic Stability Program) and TPMS became mandatory in the European Union, with also the driver seat belt reminder and the ISOFIX system, under General Safety Regulation (EC) No 661/2009. In 2015, recognizing that safer roads are a shared responsibility, Together for Safer Roads (TSR) was formally launched to align the private sector's road safety efforts with the United Nations Decade of Action for Road Safety. In 2016 and 2017, ABS became mandatory on motorcycles in the EU. In 2018, eCall became mandatory in the EU, and reverse camera in the US. In 2019, the EU legislated to revise the General Safety Regulation (GSR), the revision includes the following automotive safety features:
Sources: en.wikipedia.org
Karl Fischer titration is a standard method for measuring water content in solid and liquid samples. The result helps confirm the expected monohydrate stoichiometry. Loss-on-drying can also indicate moisture but may not distinguish water from other volatile substances.
Creatinine forms through irreversible cyclization and loss of water from creatine, and the rate increases with temperature, moisture, and pH changes. In dry solid form, the reaction is slow. In solution, degradation can become noticeable over time.
A specification typically lists assay range, water content, appearance, identification, and limits for heavy metals, residual solvents, and microbial counts. It may also include particle size distribution or bulk density for handling purposes. These parameters are distinct from any claimed performance effect.
It is a crystalline form of creatine that contains one water molecule per creatine molecule. The compound occurs naturally in muscle tissue and is also produced synthetically for research and consumer products. The monohydrate label describes the solid's hydration state.